Uncategorized
Sight Again project receives €18.5 million in funding
GenSight Biologics, Pixium Vision and Fondation Voir et Entendre announced that the Sight Again project will receive €18.5 million in funding over the next 5 years as part of the Investment for the Future, according to a press release.Sight Again is a public-private research and development project to restore vision to legally blind patients with different stages of retinitis pigmentosa. Sight Again is focused on the development of two products: an optogenetic gene therapy product (GenSight Biologics) and a vision restoration system with Prima, a retinal implant (Pixium Vision), the (Read more...)